- Country: Russia
- Summary: Drug: Empagliflosin in Favor of Citizens in Order to Social Security and Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications ...
- RUT Ref No: 116448816
- Deadline: 02 Apr 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: 17005950.00
- Notice Type: Tender
- Document Ref. No.: 0820500000825001613
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Drug: Empagliflosin in favor of citizens in order to social support and prevent the development of cardiovascular diseases and cardiovascular complications in high-risk patients located at the dispensary observation
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINDrug: Empagliflosin in Favor of Citizens in Order to Social Security and Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications ... - Russian Tender
The REGIONAL STATE STATE INSTITUTION "CENTER FOR STATE PROCUREMENT OF THE PRIMORSKY TERRITORY, a Government sector organization in Russia, has announced a new tender for Drug: Empagliflosin in Favor of Citizens in Order to Social Security and Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications .... This tender is published on RussianTenders under RUT Ref No: 116448816 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-04-02.
The estimated tender value is 17005950.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
